NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders.
Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million).
Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.
New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology s PBI-06150 Against SARS-CoV-2
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Helius Medical Technologies, Inc Appoints Sherrie Perkins to its Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Chromatin-regulating enzyme found to be a key driver of common lung cancer
A chromatin-regulating enzyme has been shown by in-depth interdisciplinary investigations to be a key driver of a common type of lung cancer. Drugs that target the enzyme could improve treatment and survival rates for this particular cancer. Squamous cell carcinoma represents nearly one third of all lung cancers in humans, says KAUST structural biologist Lukasz Jaremko, who led the research along with colleagues at Stanford University and The University of Texas MD Anderson Cancer Center, U.S. Our joint structural and dynamics investigations, including enzymatic activity studies, genetic analyses, and mouse model and human cell results, all point to the enzyme histone-lysine N-methyltransferase (NSD3) as a main driver of cancer, he says.